XML 58 R46.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 27,305 | $ 24,689 | $ 22,449
U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19,267 | 18,217 | 16,645
Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,874 | 4,135 | 3,811
Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,164 | 2,337 | 1,993
Product sales |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 27,008 | 24,355 | 22,119
Product sales | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 19,176 | 18,141 | 16,565
Product sales | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 4,678 | 3,894 | 3,567
Product sales | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,154 | 2,320 | 1,987
Total HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 16,315 | 16,938 | 16,438
Total HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12,828 | 13,651 | 13,315
Total HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,366 | 2,287 | 2,312
Total HIV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,121 | 1,000 | 811
Atripla |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 145 | 349 | 600
Atripla | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 121 | 307 | 501
Atripla | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 21 | 60
Atripla | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 12 | 21 | 39
Biktarvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 8,624 | 7,259 | 4,738
Biktarvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 7,049 | 6,095 | 4,225
Biktarvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 969 | 735 | 370
Biktarvy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 606 | 429 | 143
Complera/Eviplera |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 258 | 269 | 406
Complera/Eviplera | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 102 | 89 | 160
Complera/Eviplera | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 142 | 159 | 214
Complera/Eviplera | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 14 | 21 | 32
Descovy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,700 | 1,861 | 1,500
Descovy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,397 | 1,526 | 1,078
Descovy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 164 | 197 | 255
Descovy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 139 | 138 | 167
Genvoya |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,879 | 3,338 | 3,931
Genvoya | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2,267 | 2,605 | 2,984
Genvoya | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 391 | 490 | 664
Genvoya | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 221 | 243 | 283
Odefsey |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,568 | 1,672 | 1,655
Odefsey | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,076 | 1,172 | 1,180
Odefsey | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 440 | 450 | 438
Odefsey | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 52 | 50 | 37
Stribild |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 189 | 196 | 369
Stribild | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 132 | 125 | 268
Stribild | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 43 | 54 | 75
Stribild | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 14 | 17 | 26
Truvada |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 371 | 1,448 | 2,813
Truvada | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 314 | 1,376 | 2,640
Truvada | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 22 | 27 | 101
Truvada | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 35 | 45 | 72
Revenue share - Symtuza |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 531 | 488 | 379
Revenue share - Symtuza | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 355 | 331 | 249
Revenue share - Symtuza | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 165 | 149 | 130
Revenue share - Symtuza | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 11 | 8 | 0
Other HIV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 50 | 58 | 47
Other HIV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 15 | 25 | 30
Other HIV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 18 | 5 | 5
Other HIV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 17 | 28 | 12
Veklury |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 5,565 | 2,811 | 0
Veklury | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 3,640 | 2,026 | 0
Veklury | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,095 | 607 | 0
Veklury | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 830 | 178 | 0
Total HCV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,881 | 2,064 | 2,936
Total HCV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,018 | 1,088 | 1,465
Total HCV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 421 | 414 | 742
Total HCV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 442 | 562 | 729
Ledipasvir/Sofosbuvir |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 212 | 272 | 643
Ledipasvir/Sofosbuvir | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 84 | 92 | 312
Ledipasvir/Sofosbuvir | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 31 | 29 | 71
Ledipasvir/Sofosbuvir | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 97 | 151 | 260
Sofosbuvir/Velpatasvir |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,462 | 1,599 | 1,965
Sofosbuvir/Velpatasvir | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 815 | 864 | 971
Sofosbuvir/Velpatasvir | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 316 | 337 | 553
Sofosbuvir/Velpatasvir | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 331 | 398 | 441
Other HCV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 207 | 193 | 328
Other HCV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 119 | 132 | 182
Other HCV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 74 | 48 | 118
Other HCV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 14 | 13 | 28
Total HBV/HDV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 969 | 860 | 742
Total HBV/HDV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 397 | 380 | 343
Total HBV/HDV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 104 | 71 | 99
Total HBV/HDV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 468 | 409 | 300
Vemlidy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 814 | 657 | 488
Vemlidy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 384 | 356 | 309
Vemlidy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 34 | 29 | 21
Vemlidy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 396 | 272 | 158
Viread |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 111 | 185 | 243
Viread | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 11 | 14 | 32
Viread | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 28 | 34 | 69
Viread | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 72 | 137 | 142
Other HB/HDV |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 44 | 18 | 11
Other HB/HDV | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 2 | 10 | 2
Other HB/HDV | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 42 | 8 | 9
Other HB/HDV | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Total Cell Therapy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 871 | 607 | 456
Total Cell Therapy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 542 | 396 | 373
Total Cell Therapy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 293 | 201 | 83
Total Cell Therapy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 36 | 10 | 0
Tecartus |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 176 | 44 | 0
Tecartus | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 136 | 34 | 0
Tecartus | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 40 | 10 | 0
Tecartus | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Yescarta |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 695 | 563 | 456
Yescarta | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 406 | 362 | 373
Yescarta | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 253 | 191 | 83
Yescarta | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 36 | 10 | 0
Trodelvy |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 380 | 49 | 0
Trodelvy | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 370 | 49 | 0
Trodelvy | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 10 | 0 | 0
Trodelvy | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Total Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1,027 | 1,026 | 1,547
Total Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 381 | 551 | 1,069
Total Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 389 | 314 | 331
Total Other | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 257 | 161 | 147
AmBisome |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 540 | 436 | 407
AmBisome | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 39 | 61 | 37
AmBisome | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 274 | 230 | 234
AmBisome | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 227 | 145 | 136
Letairis |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 206 | 314 | 618
Letairis | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 206 | 314 | 618
Letairis | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Letairis | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Ranexa |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 10 | 9 | 216
Ranexa | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 10 | 9 | 216
Ranexa | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Ranexa | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 0 | 0 | 0
Zydelig |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 62 | 72 | 103
Zydelig | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 26 | 31 | 47
Zydelig | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 35 | 39 | 54
Zydelig | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 1 | 2 | 2
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 209 | 195 | 203
Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 100 | 136 | 151
Other | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 80 | 45 | 43
Other | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 29 | 14 | 9
Royalty, contract and other revenues |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 297 | 334 | 330
Royalty, contract and other revenues | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 91 | 76 | 80
Royalty, contract and other revenues | Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | 196 | 241 | 244
Royalty, contract and other revenues | Other International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total revenues | $ 10 | $ 17 | $ 6

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHCVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |